TCI GENE Inc. (TPEX:6879)
Taiwan · Delayed Price · Currency is TWD 37.00
+0.45 (1.23%)
Apr 20, 2026, 1:21 PM CST
TCI GENE Revenue
In the year 2025, TCI GENE had annual revenue of 273.61M TWD, down -21.27%. TCI GENE had revenue of 131.90M in the half year ending December 31, 2025, a decrease of -28.31%.
Revenue
273.61M
Revenue Growth
-21.27%
P/S Ratio
3.53
Revenue / Employee
n/a
Employees
n/a
Market Cap
967.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 273.61M | -73.93M | -21.27% |
| Dec 31, 2024 | 347.54M | 13.68M | 4.10% |
| Dec 31, 2023 | 333.86M | -90.17M | -21.26% |
| Dec 31, 2022 | 424.02M | -8.20M | -1.90% |
| Dec 31, 2021 | 432.22M | 239.27M | 124.01% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 736.59M |
| Meribank Biotech | 471.76M |
| Taiwan Advance Bio-Pharmaceutical | 371.86M |
| BioLASCO Taiwan | 262.66M |
| GeneReach Biotechnology | 232.74M |
| Lukas Biomedical | 180.32M |
| NatureWise Biotech & Medicals | 180.29M |
| Holy Stone Healthcare | 47.51M |